Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPACT: nab-paclitaxel (Abraxane) plus gemcitabine in locally advanced pancreatic cancer
2014-001408-23Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Celgene Corporation. Primary endpoint: Time to treatment failure. Started Nov 2014; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-001408-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001408-23.